Document Detail

The Implications of Acute Rejection and Reduced Allograft Function on Health Care Expenditures in Contemporary US Kidney Transplantation.
MedLine Citation:
PMID:  22874796     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: The economic ramifications of acute rejection (AR) are not well characterized in a contemporary population of kidney transplant recipients.
METHODS: Data for Medicare-insured transplant recipients in 2000 to 2007 (n=45,250) were drawn from the United States Renal Data System. AR events were ascertained from the Organ Procurement and Transplantation Network reports covering months 0 to 12 (yr1), 13 to 24 (yr2), and 25 to 36 (yr3) after transplantation. AR was subclassified as antibody (Ab)-treated AR or other management (non-Ab-treated AR). The marginal cost impact of AR events during and before a period of interest was quantified by multivariate linear regression including covariates for recipient, donor, and transplant factors.
RESULTS: Among recipients of standard criteria donor allografts, both Ab-treated AR events (yr1, $22,407; yr 2, $18,803; yr3, $13,909) and non-Ab-treated AR events (yr1, $14,122; yr2, $7852; yr3, $8234) were associated with significant increases in the cost of care. Patterns were similar among recipients of living donor and expanded criteria donor transplants. After weighting by population frequency, AR accounted for 2.3% to 3.8% of total costs incurred during 1 year of posttransplantation care. Subanalysis of recipients with yr1 estimated glomerular filtration rate (eGFR) information demonstrated markedly stronger cost variation across eGFR levels. For example, among those with non-Ab-treated AR, adjusted total yr2 costs were $22,747 with eGFR of 60 mL/min/1.73 m or higher but $43,881 with eGFR of 30 mL/min/1.73 m or lower.
CONCLUSIONS: AR is a significant contributor to individual posttransplantation costs. However, because of its low frequency, AR accounts for a small proportion of posttransplantation costs in the population. Healthcare costs in patients with AR are markedly higher among those with reduced compared with preserved allograft function.
Adrian Gheorghian; Mark A Schnitzler; David A Axelrod; Anupama Kalsekar; Gilbert L'italien; Krista L Lentine
Related Documents :
19559326 - Fetal lower urinary tract obstruction.
22755406 - What has changed in more than 40 years of activity and 3000 kidney transplants at polic...
912246 - Renal function in patients with hydronephrosis.
3820396 - The effect of the thromboxane a2 synthesis inhibitor oky-046 on renal function in rabbi...
20634686 - Acquired thrombotic thrombocytopenic purpura associated with reversible severe renal fa...
9089996 - Measurement of portal venous flow velocity with an implantable miniature doppler probe ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation     Volume:  94     ISSN:  1534-6080     ISO Abbreviation:  Transplantation     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  241-9     Citation Subset:  IM    
1 Saint Louis University Center for Outcomes Research, St. Louis, MO. 2 Department of Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH. 3 Global Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ. 4 Yale University School of Medicine, New Haven, CT.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patients' evaluation of hospital foodservice quality in Italy: what do patients really value?
Next Document:  Proteomics in hypertension.